

Haematologica
HAEMATOL/2019/243246
Version 3

Impact and safety of chimeric antigen receptor T cell therapy in older, vulnerable patients with relapsed/refractory large b-cell lymphoma

Richard J. Lin, Stephanie M. Lobaugh, Martina Pennisi, Hei Ton Chan, Yakup Batlevi, Josel D. Ruiz, Theresa A. Elko, Molly A. Maloy, Connie L. Batlevi, Parastoo B. Dahi, Sergio A. Giralt, Paul A. Hamlin, Elena Mead, Arela Noy, M. Lia Palomba, Bianca D. Santomasso, Craig S. Sauter, Michael Scordo, Gunjan L. Shah, Beatriz Korc-Grodzicki, Soo Jung Kim, Mari Lynne Silverberg, Chelsea A. Brooklyn, Sean M. Devlin, and Miguel-Angel Perales

Disclosures: SAG—Advisory Board for Amgen, Actinium, Celgene, Johnson & Johnson, Jazz pharmaceutical, Takeda, Novartis, Kite, Spectrum Pharma; Research funding from Amgen, Actinium, Celgene, Johnson & Johnson, Miltenyi, Takeda. CLB—Research funding from Epizyme, Novartis, Janssen, BMS, Miragen, Mediimmune; Consultancy from Defined Health. HTC—Consultancy: Atara Biotherapeutics GLS—Research funding from Janssen and Amgen. MS—Consultancy and research funding: Angiocrine Bioscience, Inc.; Consultancy: McKinsey & Company. PAH—Research support and consulting fees from Portola Pharmaceuticals, Inc. CSS—Consultant on advisory boards for: Juno Therapeutics, Sanofi Genzyme, Spectrum Pharmaceuticals, Novartis, Precision Biosciences, Kite, a Gilead Company and GSK. Research funds for investigator-initiated trials from: Juno Therapeutics and Sanofi-Genzyme. AN—Research funding from Pharmacyclics and Raphael. Honoraria from Prime Oncology, Medscape, and EUSA. Advisory Board for Janssen. MLP—Advisory Board for Celgene, Consultant for Merck and Pharmacyclics. MAP—Honoraria from Abbvie, Bellicum, Bristol-Myers Squibb, Incyte, Merck, Novartis, Nektar Therapeutics, and Takeda. He serves on DSMBs for Servier and Medigene, and the scientific advisory boards of MolMed and NexImmune. Research support for clinical trials from Incyte, Kite (Gilead) and Miltenyi Biotec.

Contributions: RJL and MAP designed the study and wrote the manuscript. RJL, SML, SMD, and MAP analyzed the data. RJL, MSP, HTC, YB, JDR, TAE, MAM, MLS, and CAB contributed essential data management. BK and SJK performed geriatric assessment. All remaining authors enrolled patients and contributed data to the study. Every author critically appraised and approved the submitted manuscript.